stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Net income
Hims & Hers Health, Inc.'s net income for fiscal 2025 was $128.4M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was −$142.0M. Over the past ten years it has ranged from −$107.7M (fiscal 2021) to $128.4M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. Hims & Hers Health, Inc. ranks 73rd of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $128.4M | 1.85% |
| FY2024 | $126.0M | — |
| FY2023 | −$23.5M | — |
| FY2022 | −$65.7M | — |
| FY2021 | −$107.7M | — |
| FY2020 | −$18.1M | — |
| FY2019 | −$72.1M | — |
| FY2018 | $0.00 | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$86.3M | — |
| Mar 2026 | −$92.1M | — |
| Dec 2025 | $20.6M | 30.60% |
| Sep 2025 | $15.8M | (62.89%) |
| 25 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| LQDA Liquidia Corporation compare | $138.6M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc compare | −$351.0K |
| HIMS Hims & Hers Health, Inc. | −$142.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on HIMS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement